NEXICART-1: Safety and Efficacy of NXC-201 in AL Amyloidosis
BCMA-directed CAR T-cell therapy (NXC-201) for AL amyloidosis showed a 100% hematologic response rate in 9 patients, with 6 achieving complete responses. Median response time was under a month, with mild cytokine release syndrome. Despite 6 deaths at 7-month follow-up, the therapy's efficacy and safety profile suggest a promising 1-shot solution for durable responses, potentially improving organ responses and AL amyloidosis management.
Reference News
BCMA-directed CAR T-cell therapy (NXC-201) for AL amyloidosis showed a 100% hematologic response rate in 9 patients, with 6 achieving complete responses. Median response time was under a month, with mild cytokine release syndrome. Despite 6 deaths at 7-month follow-up, the therapy's efficacy and safety profile suggest a promising 1-shot solution for durable responses, potentially improving organ responses and AL amyloidosis management.